Novavax COVID Vaccine Gets Authorisation For Emergency Use In Children Between 12-17 Years In US
Washington: The US Food and Drug Administration (FDA) has granted an expanded emergency use authorization for Novavax’s COVID-19 vaccine adjuvanted for adolescents aged 12-17 years. The US company said the vaccine is the first protein-based Covid-19 vaccine approved in the US. Doses of Adjuvant are available for use in adolescents at the recommendation of the … Read more
